Literature DB >> 12642053

Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.

V Hakin-Smith1, D A Jellinek, D Levy, T Carroll, M Teo, W R Timperley, M J McKay, R R Reddel, J A Royds.   

Abstract

Despite advances in the molecular pathogenesis of glioblastoma multiforme, no reliable prognostic markers have been identified. We analysed telomerase activity and telomere lengths in glioblastoma multiformes from 77 patients. 19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype. Median survival for patients with this phenotype was 542 days (95% CI 114-970) compared with 247 days (224-270) for glioblastoma multiformes with normal telomeres (p=0.0003). Cox's regression analysis showed that this association is independent of age. In patients with non-ALT tumours, telomerase activity did not affect survival (median 287 [199-375] vs 236 [230-242] days, p=0.275). We conclude that ALT is a prognostic indicator for patients with glioblastoma multiforme.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12642053     DOI： 10.1016/s0140-6736(03)12681-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  92 in total

1.  TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Authors:  Kyle Lafferty-Whyte; Alan Bilsland; Stacey F Hoare; Sharon Burns; Nadia Zaffaroni; Claire J Cairney; William Nicol Keith
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Organ aging and susceptibility to cancer may be related to the geometry of the stem cell niche.

Authors:  Krastan B Blagoev
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

Review 3.  Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.

Authors:  Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

Review 4.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

5.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

6.  Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.

Authors:  Tania Slatter; Jennifer Gifford-Garner; Anna Wiles; Xin Tan; Yu-Jen Chen; Martin MacFarlane; Michael Sullivan; Janice Royds; Noelyn Hung
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

7.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.

Authors:  Hideaki Ito; Takao Kanzawa; Toru Miyoshi; Satoshi Hirohata; Satoru Kyo; Arifumi Iwamaru; Hiroshi Aoki; Yasuko Kondo; Seiji Kondo
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

8.  Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

Authors:  Christopher M Heaphy; Andrea P Subhawong; Seung-Mo Hong; Michael G Goggins; Elizabeth A Montgomery; Edward Gabrielson; George J Netto; Jonathan I Epstein; Tamara L Lotan; William H Westra; Ie-Ming Shih; Christine A Iacobuzio-Donahue; Anirban Maitra; Qing K Li; Charles G Eberhart; Janis M Taube; Dinesh Rakheja; Robert J Kurman; T C Wu; Richard B Roden; Pedram Argani; Angelo M De Marzo; Luigi Terracciano; Michael Torbenson; Alan K Meeker
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

Review 9.  Ependymoma in children: molecular considerations and therapeutic insights.

Authors:  J-H Kim; Y Huang; A S Griffin; P Rajappa; J P Greenfield
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

10.  A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT.

Authors:  K Lafferty-Whyte; C J Cairney; M B Will; N Serakinci; M-G Daidone; N Zaffaroni; A Bilsland; W N Keith
Journal:  Oncogene       Date:  2009-08-17       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.